Organizational Changes, Agreement, New Data from Clinical Study, Conference Presentation, and Appointment - Research Report on Charles River, Medicines Co., Acorda, Allscripts, and NuVasive

NEW YORK, December 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories International, Inc. (NYSE: CRL), The Medicines Company (NASDAQ: MDCO), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), and NuVasive, Inc. (NASDAQ: NUVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Charles River Laboratories International, Inc. Research Report

On December 9, 2013, Charles River Laboratories International, Inc. (Charles River) announced organizational changes that were designed to continuously improve the Company's operating efficiency across its global portfolio and enhance its ability to meet the needs of its clients. In line with the organizational changes, Charles River's previous Corporate Executive Vice President and President of European & Asian Operations, Jorg Geller, has been appointed as Corporate Executive Vice President of Global Productivity and Efficiency, under which he will be responsible for intensifying the Company's focus on driving productivity. In addition, Davide Molho, D.V.M., the Company's previous Corporate Executive Vice President and President of North American Operations, has been appointed as Corporate Executive Vice President and President of Global Research Models & Services and Preclinical Services Operations, under which he will be responsible for global oversight of the Research Models and Services (RMS) and Preclinical Services (PCS) businesses. Colin Dunn, Ph.D., has been promoted to the position of Corporate Senior Vice President and General Manager of RMS in Europe and Asia; while Dr. Emily Hickey, Charles River's Corporate Vice President of In Vivo Discovery Research Services, will now report directly to James C. Foster, Chairman, President and CEO. The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a37e_CRL

--

The Medicines Company Research Report

On December 6, 2013, The Medicines Company (Medicines Company) and Boston Scientific Corporation (Boston Scientific) jointly announced a co-promotion agreement for the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System. The Company informed that under the terms of the agreement, Medicine Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the Promus PREMIER Stent System in U.S. hospitals, starting January 1, 2014. "This collaborative agreement brings together two of the market leading providers of interventional cardiology and acute care solutions to better support our customers and the patients they serve," said Matt Franklin, Vice President of Interventional Cardiology Global Marketing at Boston Scientific. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5a84_MDCO

--

Acorda Therapeutics, Inc. Research Report  

On December 9, 2013, Acorda Therapeutics, Inc. (Acorda) announced presentation of new data on Diazepam Nasal Spray at the 67th Annual Meeting of the American Epilepsy Society, in Washington, D.C. According to the Company, the new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics whether the drug was administered during or immediately after a seizure. "In this study, some patients received a dose of Diazepam Nasal Spray while having a seizure, while others received the dose after their seizure activity had ceased," said Adrian Rabinowicz, M.D., FAAN, Senior Vice President of Clinical Development and Medical Affairs at Acorda. "The results suggest that delivery of Diazepam Nasal Spray was unaffected by the timing of dosage relative to seizure activity. It is critical for a person with epilepsy who experiences cluster seizures that treatment be administered as soon as possible after a cluster is recognized, in order to prevent additional seizure activity." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d67c_ACOR

--

Allscripts Healthcare Solutions, Inc. Research Report

On December 9, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that the Company's management team will participate at the 32^nd Annual J.P. Morgan Healthcare Conference. According to the Company, Paul Black, President and CEO, and Rick Poulton, CFO, of Allscripts will the make the presentation on January 15, 2014 at the Westin St. Francis Hotel in San Francisco. The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1787_MDRX

--

NuVasive, Inc. Research Report

On December 4, 2013, NuVasive, Inc. (NuVasive) announced the election of Gregory T. Lucier, Chairman and CEO of Life Technologies Corporation, to the NuVasive Board of Directors. "We are exceptionally pleased to appoint Mr. Lucier to the NuVasive Board of Directors, and look forward to his contributions. His wealth of experience building and leading a growth company with a performance innovation culture will further strengthen the depth of our Board and complement the existing team well. Our ability to draw upon his prominent leadership in Life Technologies' international expansion will also be invaluable as we continue the execution of a global market share taking strategy and drive toward our next milestone of becoming a $1 Billion Start-Up," said Alex Lukianov, Chairman and CEO of NuVasive. The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c66c_NUVA

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner